About Us
CancerCare®
CancerCare is a national nonprofit organization that provides free, professional support services to individuals, families, caregivers and the bereaved to help them better cope with and manage the emotional and practical challenges arising from cancer. Our services include counseling and support groups, educational publications and workshops and financial assistance. All of our services are provided by professional oncology social workers and are offered completely free of charge. We help more than 100,000 individuals and families in all 50 states each year, and receive more than one million visits to our websites. To speak with a CancerCare social worker, call 1-800-813-HOPE (4673). Or, visit www.cancercare.org. CancerCare is not an affiliate of Boehringer Ingelheim Pharmaceuticals, Inc.
About My Cancer Circle
CancerCare and Boehringer Ingelheim Pharmaceuticals, Inc. have collaborated to provide My Cancer Circle, a free, private community to help support cancer caregivers. This service demonstrates our commitment to help people facing cancer and those who care for them every day.
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
About Boehringer Ingelheim in Oncology
Building on scientific expertise and excellence in the fields of pulmonary and cardiovascular medicine, metabolic disease, neurology, virology and immunology, Boehringer Ingelheim has embarked on a major research program to develop innovative cancer drugs. Working in close collaboration with the international scientific community and a number of the world’s leading cancer centers, Boehringer Ingelheim is committed to discovering and developing novel cancer treatments. This commitment is underpinned by using advances in science to develop a range of targeted therapies in areas of medical need. Boehringer Ingelheim’s oncology pipeline continues to evolve and demonstrates the company’s continued commitment to the disease area.
For more information, please visit http://us.boehringer-ingelheim.com and follow us on Twitter at http://twitter.com/boehringerus.
